Contrasting Femasys (NASDAQ:FEMY) and Adagio Medical (NASDAQ:ADGM)

Femasys (NASDAQ:FEMY) and Adagio Medical (NASDAQ:ADGM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Institutional and Insider Ownership

65.3% of Femasys shares are owned by institutional investors. Comparatively, 48.1% of Adagio Medical shares are owned by institutional investors. 7.7% of Femasys shares are owned by company insiders. Comparatively, 7.8% of Adagio Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Femasys has a beta of -2.07, indicating that its stock price is 307% less volatile than the S&P 500. Comparatively, Adagio Medical has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500.

Profitability

This table compares Femasys and Adagio Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Adagio Medical	N/A	-661.85%	-73.35%

Analyst Ratings

This is a breakdown of current ratings and target prices for Femasys and Adagio Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1	0	3	0	2.50
Adagio Medical	1	1	2	0	2.25

Femasys presently has a consensus price target of $50.00, indicating a potential upside of 1,830.50%. Adagio Medical has a consensus price target of $3.50, indicating a potential upside of 625.39%. Given Femasys’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Femasys is more favorable than Adagio Medical.

Earnings & Valuation

This table compares Femasys and Adagio Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29 million	9.48	-$18.63 million	($3.53)	-0.73
Adagio Medical	$600,000.00	17.86	-$25.08 million	($1.48)	-0.33

Femasys has higher revenue and earnings than Adagio Medical. Femasys is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.